Lantheus to license Bracco's CardioGen PET tracer

By staff writers

September 24, 2008 -- Lantheus Medical Imaging of North Billerica, MA, has signed a deal to license the CardioGen-82 rubidium-82 PET radiopharmaceutical from Bracco Diagnostics of Princeton, NJ.

CardioGen-82 is the only generator-based PET cardiac perfusion agent approved by the U.S. Food and Drug Administration (FDA) and reimbursed for coronary artery disease evaluation, according to the companies. The radiotracer was approved by the FDA in 1989 and has been used in hundreds of thousands of patients since then, the companies said.

CardioGen sales have been experiencing double-digit year-over-year growth since 2003, and the firms expect that the new deal will further add to the product's sales.

Definity echo contrast agent lands on FDA drug safety list, September 8, 2008

IBA, Lantheus ink radiopharma deal, July 31, 2008

Lantheus reports data from cardiac PET trial, June 17, 2008

Bracco, Novation ink supply deal, September 3, 2008

Bracco touts contrast study results, August 5, 2008

Copyright © 2008


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking